Patent · US Active

Compounds for the inhibition of herpes viruses

US8791299B2 · kind B2 · utility

0Cited by
0References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 19, 2010
Grant dateJul 29, 2014
Priority date
Expiry dateDec 2, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07C243/28
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.